RESEARCH TRIANGLE PARK, NC and SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 30, 2013) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that BREO ELLIPTA, ...

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Aug 6, 2015) - GSK (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) announce the approval in Canada of BREO® ELLIPTA® (fluticasone ...

DUBLIN--(BUSINESS WIRE)--The "Breo Ellipta" report has been added to ResearchAndMarkets.com's offering. Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol ...

GlaxoSmithKline ($GSK) has quite a bit riding on results from a trial of respiratory newcomer Breo--as in, billions of dollars in sales. And those data could come ...

U.S approval of GlaxoSmithKline’s newest respiratory inhaler continues the global drugmaker’s shift from the blockbuster drug Advair to a suite of drugs that will be assembled at the British company’s ...

DUBLIN--(BUSINESS WIRE)--The "Global BREO Ellipta Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering. The global BREO ellipta drugs market is driven ...

GlaxoSmithKline and Theravance’s Breo has been recommended for approval by an FDA advisory committee for asthma, but only in adults. Breo is already approved to treat chronic obstructive pulmonary ...

We are initiating coverage on Innoviva with a long-term Buy rating and common stock price target of $16.89 to $24. Sales of Breo and Anoro Ellipta inhalers have picked up this year due to aggressive ...

A large-scale clinical trial failed to produce anticipated results for one of GlaxoSmithKline's (GSK) respiratory disease drugs as it did not prolong the life of the tested patients and brought down ...

The company is increasing its share of new-to-brand prescriptions with Breo, and that means that “as we go forward, all else equal, we should start to see our total prescription share start to move ...